US Stock MarketDetailed Quotes

CGON CG Oncology

Watchlist
  • 28.520
  • +0.020+0.07%
Close Feb 14 16:00 ET
  • 28.520
  • 0.0000.00%
Post 16:52 ET
2.14BMarket Cap-24.46P/E (TTM)

About CG Oncology Company

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Company Profile

SymbolCGON
Company NameCG Oncology
Listing DateJan 25, 2024
Issue Price19.00
Founded2010
CEOMr. Arthur Kuan
MarketNASDAQ
Employees61
Fiscal Year Ends12-31
Address400 Spectrum Center Drive,Suite 2040
CityIrvine
ProvinceCalifornia
CountryUnited States of America
Zip Code92618
Phone1-949-409-3700

Company Executives

  • Name
  • Position
  • Salary
  • Arthur Kuan
  • Chairman of the Board and Chief Executive Officer
  • 3.74M
  • Joshua Patterson
  • General Counsel and Chief Compliance Officer
  • --
  • Dr. Vijay Kasturi, M.D.
  • Chief Medical Officer
  • 2.36M
  • Corleen M. Roche
  • Chief Financial Officer and Secretary
  • --
  • Ambaw Bellete
  • President and Chief Operating Officer
  • 2.85M
  • Dr. Leonard E. Post, PhD
  • Lead Independent Director
  • 77.54K
  • Dr. James J. Mule
  • Independent Director
  • 198.00K
  • Susan E. Graf
  • Independent Director
  • 599.04K
  • Hong Fang Song
  • Independent Director
  • --
  • Victor Tong, Jr
  • Independent Director
  • --
  • Dr. Brian Liu, M.D.
  • Independent Director
  • --

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More